title: Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.
abstract: Immune evasion is an important hallmark of cancer, and a better understanding of this mechanism is essential for the development of effective strategies against cancer. The B7 homolog 1 (B7-H1)/programmed cell death 1 (PD-1) pathway has been demonstrated as a major mechanism of immune evasion in tumor site, and its blockade therapy shows very encouraging results in clinical trials. Inducible B7-H1 expression in tumor microenvironment is complex, with multidimensional interactions and expression by different subsets of hematopoietic and nonhematopoietic cells. Understanding these interactions and how tumors take advantage of this pathway can help us design future strategies for better therapeutic efficacy and to overcome resistances.
authors.affiliation: From the Department of Immunobiology, Dermatology and Medicine (Medical Oncology) and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT.
authors.forename: Miguel F
authors.initials: MF
authors.lastname: Sanmamed
authors.forename: Lieping
authors.initials: L
authors.lastname: Chen
mesh_terms: D000818:Animals; D060890:B7-H1 Antigen / Q000276:immunology*; D006801:Humans; D056747:Immunomodulation / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology*; D059016:Tumor Microenvironment / Q000276:immunology
chemical_list: D060890:B7-H1 Antigen
references.citation: Nature. 2006 Feb 9;439(7077):682-7
references.pmid: 16382236
references.citation: Cancer Immunol Res. 2014 Apr;2(4):361-70
references.pmid: 24764583
references.citation: Blood. 2010 Aug 26;116(8):1291-8
references.pmid: 20472828
references.citation: Blood. 2008 Apr 1;111(7):3635-43
references.pmid: 18223165
references.citation: Int Immunol. 2007 Oct;19(10):1223-34
references.pmid: 17898045
references.citation: J Immunol. 2007 May 1;178(9):5552-62
references.pmid: 17442937
references.citation: Lab Invest. 2014 Jan;94(1):107-16
references.pmid: 24217091
references.citation: N Engl J Med. 2013 Jul 11;369(2):122-33
references.pmid: 23724867
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2691-7
references.pmid: 22614989
references.citation: N Engl J Med. 2013 Jul 11;369(2):134-44
references.pmid: 23724846
references.citation: J Immunol. 2006 Nov 1;177(9):5928-35
references.pmid: 17056517
references.citation: Nat Med. 2010 Apr;16(4):452-9
references.pmid: 20208540
references.citation: N Engl J Med. 2013 Apr 4;368(14):1365-6
references.pmid: 23550685
references.citation: J Clin Oncol. 2013 Feb 10;31(5):616-22
references.pmid: 23295794
references.citation: N Engl J Med. 2012 Jun 28;366(26):2455-65
references.pmid: 22658128
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Cancer Immunol Res. 2013 Jul;1(1):32-42
references.pmid: 24777248
references.citation: Annu Rev Immunol. 2008;26:677-704
references.pmid: 18173375
references.citation: Cancer J. 2011 Sep-Oct;17(5):343-50
references.pmid: 21952285
references.citation: Sci Transl Med. 2012 Mar 28;4(127):127ra37
references.pmid: 22461641
references.citation: FEBS Lett. 2006 Feb 6;580(3):755-62
references.pmid: 16413538
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4275-80
references.pmid: 20160101
references.citation: J Exp Med. 2000 Oct 2;192(7):1027-34
references.pmid: 11015443
references.citation: J Exp Med. 2014 May 5;211(5):943-59
references.pmid: 24752301
references.citation: Science. 1995 Nov 10;270(5238):985-8
references.pmid: 7481803
references.citation: Neoplasia. 2006 Mar;8(3):190-8
references.pmid: 16611412
references.citation: Nat Med. 2003 May;9(5):562-7
references.pmid: 12704383
references.citation: Nat Rev Immunol. 2008 Jun;8(6):467-77
references.pmid: 18500231
references.citation: Cancer Res. 2014 Aug 1;74(15):4042-52
references.pmid: 24812273
references.citation: Science. 2008 Oct 10;322(5899):271-5
references.pmid: 18845758
references.citation: J Immunol. 2003 Apr 1;170(7):3637-44
references.pmid: 12646628
references.citation: Oncoimmunology. 2013 Mar 1;2(3):e23403
references.pmid: 23802081
references.citation: Immunity. 2007 Jul;27(1):111-22
references.pmid: 17629517
references.citation: J Immunol. 2008 Nov 1;181(9):5842-6
references.pmid: 18941172
references.citation: Clin Cancer Res. 2009 Oct 15;15(20):6341-7
references.pmid: 19825956
references.citation: Clin Cancer Res. 2013 Oct 1;19(19):5542
references.pmid: 24048329
references.citation: J Immunol. 2002 Oct 1;169(7):3581-8
references.pmid: 12244148
references.citation: Eur J Cancer. 2014 May;50(7):1361-9
references.pmid: 24548766
references.citation: Nat Med. 2002 Aug;8(8):793-800
references.pmid: 12091876
references.citation: J Exp Med. 2012 Jun 4;209(6):1201-17
references.pmid: 22641383
references.citation: J Exp Med. 2013 Aug 26;210(9):1695-710
references.pmid: 23897981
references.citation: Nature. 2001 May 17;411(6835):380-4
references.pmid: 11357146
references.citation: Nat Med. 1999 Dec;5(12):1365-9
references.pmid: 10581077
references.citation: Nat Med. 2007 Jan;13(1):84-8
references.pmid: 17159987
references.citation: Blood. 2003 Apr 1;101(7):2514-20
references.pmid: 12468426
references.citation: Cancer Res. 2005 Feb 1;65(3):1089-96
references.pmid: 15705911
references.citation: Immunity. 2004 Mar;20(3):327-36
references.pmid: 15030776
references.citation: Adv Immunol. 2006;90:51-81
references.pmid: 16730261
references.citation: Cancer Discov. 2013 Dec;3(12):1355-63
references.pmid: 24078774